Gastrooesophageal cancer+1
RecruitingStudy on Trastuzumab Deruxtecan and Fluorouracil for Patients with HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease
Study on Trastuzumab Deruxtecan and Fluorouracil for Patients with HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease
- Disease:Gastrooesophageal cancerGastric cancer
- Substances:Anhydrous DocetaxelCalcium Folinate+4
Italy- Participants:18–64 years · 65+ years
- Substances:Anhydrous Docetaxel
- Sponsor:Fondazione GONO G.I.







